Image source

Cannabis stocks rebounded on June 24 (LPs + 2.9%; MSOs +3.6%) amid easing geopolitical tensions, renewed hopes for U.S. reform momentum and a mix of strong fundamentals and renewed investor interest. That rising tide propelled Organigram Global by 6.3% along with its peers. Specifically, OGI jumped thanks to:

1. Momentum from record Q2 results: OGI had recently reported second-quarter 2025 net sales that were up 74% year-over-year, beating consensus estimates. That kind of top-line growth—especially in a tough cannabis market—caught investors’ attention.
2. Bullish sentiment around international expansion: The company flagged strong growth in international medical cannabis sales, particularly in Europe with Germany’s medical market expanding and other EU countries opening up, OGI’s export strategy looked increasingly attractive.
3. Speculation around strategic partnerships: British American Tobacco (BAT), which already owns a stake in Organigram, has been rumored to be eyeing deeper involvement. While nothing official has been announced, the possibility of a buyout or expanded JV added fuel to the rally.

About Organigram Global

Organigram Global Inc. engages in the production and sale of:

• medical cannabis products,
• adult use recreational cannabis,
• cannabis-derived products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates in Canada and 
• in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers.

Stock Price Forecast and Analyst Ratings

There is currently no analyst price target forecast or ratings available for Organigram Global.

More By This Author:

These 6 AI Hardware Stocks Were Up +6% On June 24th - Here's Why
Quantum Computing Inc. Plunged 7% June 23rd Driven By A Perfect Storm Of Events
Cannabis LP Stock Tilray Brands (TLRY) Declined 10% Last Week - Here's Why